Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acetylator phenotype in systemic lupus erythematosus.

B Foad, A Litwin, H Zimmer

    Arthritis and Rheumatism
    |April 1, 1977
    PubMed
    Summary

    Systemic lupus erythematosus (SLE) patients show a higher prevalence of slow sulfamethazine acetylation (68%) than the general population (52%). Slow acetylators also exhibited reduced lymphocyte response to phytomitogens.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Evaluation of a hepatitis C clinical care coordination programme's effect on treatment initiation and cure: A surveillance-based propensity score matching approach.

    Journal of viral hepatitis·2018
    Same author

    Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all.

    Journal of viral hepatitis·2016
    Same author

    Bioaccumulation and molecular effects of sediment-bound metals in zebrafish embryos.

    Environmental science and pollution research international·2015
    Same author

    The immune profile of human seminal plasma.

    Immunology today·2014
    Same author

    Halitosis--a common medical and social problem. A review on pathology, diagnosis and treatment.

    Acta gastro-enterologica Belgica·2012
    Same author

    Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.

    British journal of cancer·2009

    Area of Science:

    • Pharmacogenetics
    • Immunology
    • Rheumatology

    Background:

    • Sulfamethazine acetylation is a key metabolic pathway influenced by genetic factors.
    • Systemic lupus erythematosus (SLE) is an autoimmune disease with complex pathogenesis.
    • Previous studies suggest potential differences in drug metabolism in SLE patients.

    Purpose of the Study:

    • To investigate the acetylator phenotype of sulfamethazine in patients with SLE.
    • To determine if there is a correlation between acetylator phenotype and clinical manifestations or disease activity in SLE.
    • To assess the relationship between acetylator phenotype and lymphocyte response to phytomitogens in SLE patients.

    Main Methods:

    • Studied the sulfamethazine acetylation rate in 25 patients diagnosed with SLE.
    • Compared the observed acetylation rates in SLE patients to established population data.
    • Analyzed correlations between acetylator phenotype, clinical features, disease activity, and lymphocyte response to phytomitogens.

    Main Results:

    • 68% of SLE patients (17 out of 25) were identified as slow acetylators, a significantly higher rate than the general population's 52%.
    • No significant correlation was found between the acetylator phenotype and the clinical manifestations or disease activity in SLE patients.
    • SLE patients who were slow acetylators demonstrated a diminished lymphocyte response to phytomitogens compared to rapid acetylators.

    Conclusions:

    • The prevalence of slow sulfamethazine acetylation is elevated in SLE patients.
    • Acetylator phenotype does not appear to correlate with SLE clinical presentation or disease activity.
    • Slow acetylation in SLE may be associated with impaired cellular immune responses, specifically reduced lymphocyte reactivity.

    Related Experiment Videos